Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Veterans Administration Medical Center-Baltimore — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Christiana Care - Union Hospital — Elkton, Maryland
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Maryland: - Baltimore Veterans Affairs Medical Center ( Site 0069) — Baltimore, Maryland
- Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland
- Chesapeake Urology ( Site 0009) — Towson, Maryland
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Maryland: - Greenebaum Comprehensive Cancer Center ( Site 0021) — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Maryland: - University of Maryland — Baltimore, Maryland
- Johns Hopkins Hospital — Baltimore, Maryland
- Johns Hopkins Medical Institutions — Baltimore, Maryland
- Chesapeake Urology Research Associates — Towson, Maryland
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Maryland: - Baltimore Veterans Affairs Medical Center ( Site 0069) — Baltimore, Maryland
- Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Maryland: - Research Site — Bethesda, Maryland
- Research Site — Towson, Maryland
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Maryland: - Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
- FMH James M Stockman Cancer Institute — Frederick, Maryland
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Maryland: - Site US10029 — Towson, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in Maryland: - University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07181161
Sites in Maryland: - Research Site — Towson, Maryland
Phase 2 Recruiting Academic/Other
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT05223803
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- UMMC — Baltimore, Maryland
- Upper Chesapeake Health — Bel Air, Maryland
- Central Maryland Radiation Oncology — Columbia, Maryland
- Baltimore Washington Medical Center — Glen Burnie, Maryland
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06353386
Sites in Maryland: - University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04363164
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06014255
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and has mutation(s) in deoxyribonucleic acid (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04550494
Sites in Maryland: - National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropr…
Sponsor: AtlasMedx, Incorporated
NCT ID: NCT04503265
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imagin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05155046
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI…
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04698564
Sites in Maryland: - University of Maryland Medical Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive diseas…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04704505
Sites in Maryland: - Amber Michalik — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07142551
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland